Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus

Circulation. 2017 Aug 8;136(6):602-604. doi: 10.1161/CIRCULATIONAHA.117.028745.
No abstract available

Keywords: morphine cloride; myocardial infarction; platelet antagonists; platelet function test; prasugrel hydrochloride; ticagrelor.

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Diabetes Mellitus / blood*
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / drug therapy
  • Drug Resistance
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Insulin / administration & dosage
  • Percutaneous Coronary Intervention* / adverse effects
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Function Tests
  • Prasugrel Hydrochloride / administration & dosage*
  • Prasugrel Hydrochloride / adverse effects
  • Prospective Studies
  • Purinergic P2Y Receptor Antagonists / administration & dosage*
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Receptors, Purinergic P2Y12 / blood
  • Receptors, Purinergic P2Y12 / drug effects
  • Risk Factors
  • ST Elevation Myocardial Infarction / blood
  • ST Elevation Myocardial Infarction / diagnosis
  • ST Elevation Myocardial Infarction / therapy*
  • Ticagrelor / administration & dosage*
  • Ticagrelor / adverse effects
  • Treatment Outcome

Substances

  • Hypoglycemic Agents
  • Insulin
  • P2RY12 protein, human
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Prasugrel Hydrochloride
  • Ticagrelor